Imiquimod in Children With Plaque Morphea

Inclusion Criteria: * Age at diagnosis 6 to 18 years of age * Morphea plaques * Female subjects of childbearing potential must have a negative urine pregnancy test * Signed consent/assent form Exclusion criteria: * Children who received topical corticosteroids, tacrolimus, vitamin D derivatives (calcipotriol, calcipotriol-betamethasone dipropionate) to the affected area in the previous four weeks * Children who were previously treated with Imiquimod on the affected areas * Children with no demonstrable ultrasonographic changes at the baseline evaluation * Children with evidence of skin breakdown on the proposed area to be treated at the time of enrollment due to potential increased absorption of the medication through impaired skin barrier * Female subjects of childbearing potential who do not agree to practice effective birth control methods for the duration of the study * Children who are/were (in the past 6 months) treated with systemic medications such as methotrexate and/or systemic corticosteroids * Co-morbidities: systemic sclerosis, juvenile rheumatoid arthritis, other systemic diseases